These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

850 related articles for article (PubMed ID: 25573987)

  • 1. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.
    Jacobsen ED; Sharman JP; Oki Y; Advani RH; Winter JN; Bello CM; Spitzer G; Palanca-Wessels MC; Kennedy DA; Levine P; Yang J; Bartlett NL
    Blood; 2015 Feb; 125(9):1394-402. PubMed ID: 25573987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry.
    Bartlett NL; Smith MR; Siddiqi T; Advani RH; O'Connor OA; Sharman JP; Feldman T; Savage KJ; Shustov AR; Diefenbach CS; Oki Y; Palanca-Wessels MC; Uttarwar M; Li M; Yang J; Jacobsen ED
    Leuk Lymphoma; 2017 Jul; 58(7):1607-1616. PubMed ID: 27868471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.
    Horwitz SM; Advani RH; Bartlett NL; Jacobsen ED; Sharman JP; O'Connor OA; Siddiqi T; Kennedy DA; Oki Y
    Blood; 2014 May; 123(20):3095-100. PubMed ID: 24652992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD30: seeing is not always believing.
    Blum KA
    Blood; 2015 Feb; 125(9):1358-9. PubMed ID: 25721040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
    Narayan R; Blonquist TM; Emadi A; Hasserjian RP; Burke M; Lescinskas C; Neuberg DS; Brunner AM; Hobbs G; Hock H; McAfee SL; Chen YB; Attar E; Graubert TA; Bertoli C; Moran JA; Bergeron MK; Foster JE; Ramos AY; Som TT; Vartanian MK; Story JL; McGregor K; Macrae M; Behnan T; Wey MC; Rae J; Preffer FI; Lesho P; Duong VH; Mann ML; Ballen KK; Connolly C; Amrein PC; Fathi AT
    Cancer; 2020 Mar; 126(6):1264-1273. PubMed ID: 31860140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies.
    Bartlett NL; Chen R; Fanale MA; Brice P; Gopal A; Smith SE; Advani R; Matous JV; Ramchandren R; Rosenblatt JD; Huebner D; Levine P; Grove L; Forero-Torres A
    J Hematol Oncol; 2014 Mar; 7():24. PubMed ID: 24642247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial.
    Kim SJ; Yoon DH; Kim JS; Kang HJ; Lee HW; Eom HS; Hong JY; Cho J; Ko YH; Huh J; Yang WI; Park WS; Lee SS; Suh C; Kim WS
    Cancer Res Treat; 2020 Apr; 52(2):374-387. PubMed ID: 31476851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies.
    Forero-Torres A; Fanale M; Advani R; Bartlett NL; Rosenblatt JD; Kennedy DA; Younes A
    Oncologist; 2012; 17(8):1073-80. PubMed ID: 22855426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program.
    Perrot A; Monjanel H; Bouabdallah R; Quittet P; Sarkozy C; Bernard M; Stamatoullas A; Borel C; Bouabdallah K; Nicolas-Virelizier E; Fournier M; Morschhauser F; Brice P;
    Haematologica; 2016 Apr; 101(4):466-73. PubMed ID: 26768687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Cases.
    Albany C; Einhorn L; Garbo L; Boyd T; Josephson N; Feldman DR
    Oncologist; 2018 Mar; 23(3):316-323. PubMed ID: 29222199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma.
    Ogura M; Tobinai K; Hatake K; Ishizawa K; Uike N; Uchida T; Suzuki T; Aoki T; Watanabe T; Maruyama D; Yokoyama M; Takubo T; Kagehara H; Matsushima T
    Cancer Sci; 2014 Jul; 105(7):840-6. PubMed ID: 24814862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brentuximab vedotin demonstrates an objective response in a patient with refractory CD30+ primary mediastinal B-cell lymphoma.
    Badri N; Ngamdu KS; Torabi A; Guar S
    J Cancer Res Ther; 2020; 16(1):183-185. PubMed ID: 32362635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
    Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
    Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.
    Younes A; Gopal AK; Smith SE; Ansell SM; Rosenblatt JD; Savage KJ; Ramchandren R; Bartlett NL; Cheson BD; de Vos S; Forero-Torres A; Moskowitz CH; Connors JM; Engert A; Larsen EK; Kennedy DA; Sievers EL; Chen R
    J Clin Oncol; 2012 Jun; 30(18):2183-9. PubMed ID: 22454421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience.
    Rothe A; Sasse S; Goergen H; Eichenauer DA; Lohri A; Jäger U; Bangard C; Böll B; von Bergwelt Baildon M; Theurich S; Borchmann P; Engert A
    Blood; 2012 Aug; 120(7):1470-2. PubMed ID: 22786877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies.
    Han TH; Chen R; Advani R; Berryman RB; Smith SE; Forero-Torres A; Rosenblatt JD; Smith MR; Zain J; Hunder NN; Engert A
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):241-9. PubMed ID: 23719719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Classical Hodgkin lymphoma primary refractory to brentuximab vedotin, with transformation to CD30-positive diffuse large B-cell lymphoma.
    Makita S; Maeshima AM; Taniguchi H; Kitahara H; Fukuhara S; Munakata W; Suzuki T; Maruyama D; Kobayashi Y; Tobinai K
    Int J Hematol; 2016 Sep; 104(3):396-9. PubMed ID: 27169615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.
    Fanale MA; Horwitz SM; Forero-Torres A; Bartlett NL; Advani RH; Pro B; Chen RW; Davies A; Illidge T; Huebner D; Kennedy DA; Shustov AR
    J Clin Oncol; 2014 Oct; 32(28):3137-43. PubMed ID: 25135998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brentuximab vedotin use in pediatric anaplastic large cell lymphoma.
    Agrusa JE; Egress ER; Lowe EJ
    Front Immunol; 2023; 14():1203471. PubMed ID: 37275877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review.
    Berger GK; McBride A; Lawson S; Royball K; Yun S; Gee K; Bin Riaz I; Saleh AA; Puvvada S; Anwer F
    Crit Rev Oncol Hematol; 2017 Jan; 109():42-50. PubMed ID: 28010897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.